Obermatt
See Similar Stocks →

Flags

Financial distress

Humacyte

NSQ:HUMA · US44486Q1031
BiotechnologySmall

360

4
Profit price47
Owner Earnings Yield1
Dividend Yield1
Price/Sales36
Price/Book87
Return on Capital21
Cash Return on Capital4
Return on Equity1
Profit margins5
Accruals34
Owner Earnings Margin14
Sales growth93
Profit growth80
Reinvestment7
Price momentum10
Debt load9
Refinancing93
Debt Payback1
Liquidity72
Analyst ratings19
Opinion Changes4
Price Target Upside41
Market mood94
Value Creation10/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Humacyte clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2020
Employees160
Websitehumacyte.com
ISINUS44486Q1031
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
CardiovascularDefenseTechBiomedical EngineeringDiabetesStem Cell TherapyNephrologySurgeryBiotechnologyMedicalMedical Device

Description

Humacyte, Inc. (Humacyte) operates as a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale. The company develops and manufactures off-the-shelf, universally implantable…

Analysis

Weak and unloved

Humacyte, Inc. is weak and unloved: below-average business metrics and a price that reflects that disappointment.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is stretched. The company scores 10/20 on our value-creation score: creating some value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
66
2026

All-time high

80

Mar 2026

All-time low

66

Jun 2026

Average rank

73

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
36
—
—
—
Price/Earnings
52
—
—
—
Price/Book
87
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
64
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Humacyte with its peers
Edgewise Therapeutics
NSQ:EWTX
49
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Dianthus Therapeutics
NAQ:DNTH
20
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
NovaBridge Biosciences
NMQ:NBP
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Dyne Therapeutics
NSQ:DYN
34
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Larimar Therapeutics
NMQ:LRMR
26
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Rezolute
NAQ:RZLT
53
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →